Aberrant expression of Secreted Protein Acidic and Rich in Cysteine (SPARC)/osteonectin has been associated with an invasive tumor cell phenotype and poor outcome in human melanomas. Although it is known that SPARC controls melanoma tumorigenesis, the precise role of SPARC in melanoma cell survival is still unclear. Here, we show that SPARC has a cell-autonomous survival activity, which requires Akt-dependent regulation of p53. Suppression of SPARC by RNA interference in several human melanoma cells and xenografted A375 tumors triggers apoptotic cell death through the mitochondrial intrinsic pathway and activation of caspase-3. Cell death induced by depletion of SPARC is dependent on p53 and induction of Bax, and results in the generation of ROS. Stabilization of p53 in SPARC-depleted cells is associated with a decrease in Akt-mediated activating phosphorylation of MDM2. Inhibition of Akt signaling pathway is important for the observed changes as overexpression of constitutively active Akt protects cells against apoptosis induced by SPARC depletion. Conversely, increased expression of SPARC stimulates Akt and MDM2 phosphorylation, thus facilitating p53 degradation. Finally, we show that overexpression of SPARC renders cells more resistant to the p53-mediated cytotoxic effects of the DNA-damaging drug actinomycin-D. Our study indicates that SPARC functions through activation of Akt and MDM2 to limit p53 levels and that acquired expression of SPARC during melanoma development would confer survival advantages through suppression of p53-dependent apoptotic pathways.
Introduction
Melanoma is the leading cause of skin cancer-related deaths and its incidence has increased worldwide faster than any other cancer. Despite intensive research, the overall 5-year survival for metastatic melanoma patients remains less than 10%. Hallmarks of melanoma are its propensity to rapidly spread to the lymph system and internal organs, and its unresponsiveness to radiation and chemotherapy. Local forms of the disease can be cured by surgical excision, but there are no effective treatment options available for advanced melanomas.
Melanomas arise from malignant transformation of epidermal melanocytes and develop as multistep process through accumulation of genetic and epigenetic changes in growth and survival pathways, as well as alterations in cell-cell communication and extracellular matrix interactions (Miller and Mihm, 2006) . Matricellular proteins are found in the extra-and pericellular matrix, and are potent modulators of cellular functions and tumorstroma interactions (Bornstein and Sage, 2002) . Expression of some members of the matricellular proteins family is altered during the development of melanoma (FukunagaKalabis et al., 2008) . For example, Secreted Protein Acidic and Rich in Cysteine (SPARC) (also called osteonectin and BM-40) is abundantly produced by melanoma cells but is not expressed by normal melanocytes (Ledda et al., 1997a; Robert et al., 2006) . Its expression correlates with the aggressiveness of melanomas and adverse clinical outcome (Massi et al., 1999) . SPARC was shown to be multifunctional, with activities in differentiation, apoptosis, cancer cell migration and regulation of immune cell response (Arnold and Brekken, 2009 ). Mechanistically, SPARC binds to several components of the extracellular matrix and interacts with specific adhesion receptors such as integrin-b1 (Nie et al., 2008; Weaver et al., 2008) . The intracellular signaling pathways downstream from SPARC are beginning to be identified. They include major mediators of integrin signaling such as integrin-linked kinase (ILK) and focal adhesion kinase (FAK) (Barker et al., 2005; Shi et al., 2007; Weaver et al., 2008) , as well as b-catenin and phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathways (Shi et al., 2004; Nie and Sage, 2009; Chang et al., 2010) . In cancer, SPARC may function as either a tumor suppressor or a pro-invasive factor depending on the tumor type and local extracellular milieu.
Several lines of evidence have strengthened the notion that production of SPARC by tumor cells is critical for melanoma progression. We and others have shown that SPARC promotes migratory and invasive abilities of human melanoma cells (Robert et al., 2006; Smit et al., 2007) . Moreover, SPARC was shown to control melanoma growth in xenograft assays and cell-cycle progression in cultured cells (Ledda et al., 1997b; Horie et al., 2010; Fenouille et al., 2011) . We recently showed that RNA interference-mediated depletion of SPARC in melanoma cells activates p53 and induces p21
Cip1/Waf1 -dependent cell-cycle arrest, raising the possibility that SPARC might have a role in p53 tumor-suppressor regulation in melanoma cells (Fenouille et al., 2011) .
The acquisition of survival pathways promoting resistance to apoptosis is a common feature of tumor cells and contributes to tumorigenesis, metastasis and drug resistance (Johnstone et al., 2002) . p53-mediated apoptosis has a central role in suppression of tumorigenesis (Vogelstein et al., 2000) . Under normal conditions, intracellular levels of p53 are controlled by the E3 ubiquitin ligase MDM2, which binds to p53 and promotes its ubiquitination and degradation by the proteasome (Honda et al., 1997; Marine et al., 2006) . One of the major regulators of MDM2 activity is Akt, which phosphorylates MDM2 at Ser166 and Ser186 (Mayo and Donner, 2001; Zhou et al., 2001; Ogawara et al., 2002) . Akt is an important pro-survival molecule, and phosphorylation of MDM2 may serve to protect cells from p53-induced apoptotic cell death.
In response to various cellular stresses, p53 transcriptionally induces the expression of specific target genes, which critically regulate the mitochondrial intrinsic apoptotic pathway and mediate tumor-suppressive functions (Vogelstein et al., 2000) . An important downstream mediator of this pathway is Bax (Miyashita and Reed, 1995) . The apoptotic stress causes Bax transactivation and its translocation from cytosol to mitochondria, leading to the efflux of cytochrome c from mitochondria, the assembly of apoptosome and caspase-9 activation, followed by activation of effector caspases (Schuler and Green, 2001) . Consequently, the p53 apoptosis pathway is disrupted in most human cancers by mutation in p53, or altered expression of downstream effectors or upstream regulators of p53 (Vogelstein et al., 2000) . Unlike other cancers, p53 is rarely mutated in melanoma (Weiss et al., 1993; Albino et al., 1994) . Thus, melanoma cells typically harbor functional p53 protein but acquire capacities to inactivate components of the p53 pathway and to evade stress-induced cell death (Soengas and Lowe, 2003) .
In this study, we investigated whether SPARC can provide melanoma cells with survival advantage and suppress the ability of p53 to activate the cell death machinery. By combining gene silencing (through RNA interference strategies) and overexpression studies in human melanoma cells, followed by functional rescue experiments, we now show that SPARC can override p53-mediated apoptosis by activating Akt and MDM2. We not only define a contribution of SPARC in melanoma cell survival, but also determine a novel mechanism by which SPARC promotes resistance to p53-mediated cell death.
Results

SPARC deficiency reduces clonogenicity and promotes time-dependent apoptosis
We began by addressing the effect of SPARC knockdown in melanoma cell proliferation and cell-cycle distribution using small interfering RNA (siRNA). Treatment of A375, 1205Lu and 501mel cells with SPARC siRNA (siSPARC) for 6 days resulted in a dramatic decrease in cellular proliferation as measured by XTT assay (Supplementary Figure S1A) . Cell-cycle profiles were examined with A375 cells, which were transfected with control or SPARC siRNA, and as we described (Fenouille et al., 2011) , SPARC depletion induced a significant increase in the cell population in the G 2 /M phase after 4 days ( Figure 1a) . However, the increasing number of sub-G 1 cells at day 5 and 6 indicated an occurrence of subsequent cell death. To assess the effects of SPARC knockdown on cell-cycle progression and cell death beyond 6 days, we performed clonogenic survival assays. We used A375 clones that stably express a doxycycline-inducible short-hairpin RNA (shRNA) construct targeting another sequence in the SPARCcoding region (shSPARC #3F9 and #5H9 cells). SPARC protein was knocked down approximately 90% after doxycycline exposure of cells (Supplementary Figure S1B) , and this resulted in decreased ability of A375 cells to form foci and soft agar colonies, showing that SPARC is required for the clonogenic survival of melanoma cells (Figure 1b and Supplementary Figure S1C) .
To confirm and extend the findings on cell death, we used Annexin-V binding and flow cytometry to analyze apoptosis in A375 cells following downregulation of SPARC expression by siRNA or shRNA (Figure 1c ). TRAIL treatment served as a positive control for apoptosis. Fluorescence-activated cell sorting analysis clearly showed an increase in the number of cells that stained positive for the apoptotic marker Annexin-V, 5 days following SPARC knockdown. After 5 days of depletion by siRNA, the Annexin-V-positive cells increased to 15% to reach 25% at day 6, which showed that SPARC-knockdown A375 cells activate apoptotic death. Apoptosis was also evidenced in 1205Lu and 501mel cells following treatment with siSPARC for 6 days ( Figure 1d ). Immunoblot analysis confirmed PARP cleavage, a marker of cells undergoing apoptosis, following siSPARC treatment or induction of SPARC shRNA in melanoma cells (Figures 1e and f) .
SPARC deficiency activates the mitochondria-dependent apoptotic pathway To further characterize the apoptotic response, we measured activity of the effector caspase-3 by fluori- activation was also detected in 1205Lu and 501mel melanoma cells 6 days after transfection with siSPARC ( Figure 2c ). To distinguish the apoptotic signaling pathways activated in SPARC-depleted cells, caspase-8 (d) 1205Lu and 501mel were transfected with 50 nM siCTRL or siSPARC for 6 days before being stained with Annexin-V-fluos, and analyzed by flow cytometry as above. (e) A375 cells were transfected for various time periods with 50 nM siCTRL or siSPARC (left panel). A375 shlacZ or shSPARC (clone #3F9) were grown for 7 days in doxycycline-free medium (ÀDox) or Doxycyclinecontaining medium ( þ Dox) (right panel). Protein lysates from the resulting cells were analyzed by immunoblotting using the indicated antibodies. Detection of PARP cleavage (cl. PARP) was used as a marker for apoptosis and HSP60 as a loading control. (f) 1205Lu and 501mel cells were transfected with 50 nM siCTRL or siSPARC for 6 days and protein lysates were analyzed for PARP cleavage by immunoblotting. PI, propidium iodide; siRNA, small interfering RNA; shRNA, short-hairpin RNA; SPARC, secreted protein acidic and rich in cysteine.
Antiapoptotic function of SPARC in melanoma cells N Fenouille et al and caspase-9 activities were determined by specific enzymatic assays. Caspase-9 activation, the key initiator of the mitochondrial intrinsic pathway occurred from day 5 to day 6 following SPARC siRNA treatment ( Figure 2d ). By contrast, caspase-8, the initiator caspase typically involved in receptor-mediated apoptosis, was not active under these conditions, whereas TRAIL administration led to its effective activation. This strongly suggests that SPARC depletion initiates the mitochondrial apoptotic pathway. We next examined whether apoptosis upon SPARC depletion can be observed in a mouse xenograft model of melanoma. We injected nude mice subcutaneously with A375 shSPARC cells and treated the mice with doxycycline to switch off SPARC in tumor tissues. As we reported previously by Fenouille et al. (2011) , inhibiting SPARC expression in A375 shSPARC tumors yielded slower-growing tumors compared with the untreated group of mice (Figure 2e ). At the end of the study, analysis of caspase-3 activities of tumor tissues showed that caspase-3 was significantly activated in SPARC-depleted tumors but not in SPARC-positive tumors. Immunoblot analysis of xenograft protein extracts confirmed effective depletion of SPARC in tumors derived from doxycycline-treated mice. These data indicate that the antitumor effects of SPARC depletion can be caused by induction of apoptotic death.
p53 induces apoptosis and ROS production in SPARCdepleted melanoma cells A main known function of p53 is to elicit mitochondrial apoptotic events (Schuler and Green, 2001 ). As we showed recently that p53 is upregulated and activated in melanoma cells following siRNA-mediated SPARC depletion (Fenouille et al., 2011) , we asked whether p53 is involved in the above-described apoptotic response. Immunoblot analysis showed a rapid and Antiapoptotic function of SPARC in melanoma cells N Fenouille et al significant time-dependent increase of p53 protein levels in A375 cells exposed to siSPARC (Figure 3a ). p53 levels were also elevated in A375 shSPARC tumors from mice that received doxycycline treatment (Figure 3b ).
We next investigated whether knockdown of p53 by siRNA can rescue SPARC-depleted cells from apoptosis. Simultaneous knockdown of SPARC and p53 did not cause caspase-3 activation and PARP degradation, Figure S2 for other data obtained in SKmel 28 cells. (f) Measurement of ROS levels using the redox-sensitive fluorescent dye DCF-DA. A375 cells were transfected with 50 nM siCTRL or siSPARC for the indicated time periods (top panel), or with siCTRL, sip53, siSPARC alone or in combination at 50 nM for 6 days (bottom panel). After incubation with 10 mM DCF-DA, the cells were analyzed by flow cytometry. Similar results were obtained in TP53 wt 1205Lu and 501mel cells (see Supplementary Figure S3 ). ROS, reactive oxygen species; siRNA, small interfering RNA; SPARC, secreted protein acidic and rich in cysteine.
Antiapoptotic function of SPARC in melanoma cells N Fenouille et al compared with SPARC knockdown alone (Figure 3c) . Accordingly, the concurrent depletion of p53 prevented the increase of Annexin-V-positive cells observed in SPARC-depleted cells (Figure 3d ), indicating that apoptosis induced by siSPARC is p53-dependent. Further evidence for the importance of p53 came from experiments performed in SKmel28 melanoma cells containing mutant p53. Annexin-V labeling, PARPcleavage and XTT assays showed that these cells were resistant to apoptosis induced by SPARC knockdown (Figure 3e and Supplementary Figure S2) .
It is known that generation of reactive oxygen species (ROS) represents a primary event in the regulation of p53-induced apoptosis (Johnson et al., 1996) . Consequently, ROS levels were monitored by cytometric analysis in melanoma cells exposed to siSPARC using the fluorescent probe DCF-DA. The fluorescent intensity increased gradually in a time-dependent manner upon SPARC depletion in A375, 1205Lu and 501mel cells (Figure 3f and Supplementary Figures S3A and B) , suggesting that generation of ROS is involved in the apoptotic process. This increase in ROS was also dependent on p53, as depletion of p53 by siRNA inhibited SPARC siRNA-induced ROS production observed 4 days after transfection (Figure 3f ). Finally, we examined the functional contribution of ROS to apoptosis induced by SPARC knockdown and found that treatment with the radical scavenger N-acetyl-Lcysteine prevented ROS generation and attenuated siSPARC-mediated caspase-3 activation (Supplementary Figure S3C ), suggesting that ROS generation is partially involved in apoptosis. Also, our observation that the pan-caspase inhibitor z-VAD-fmk was unable to prevent ROS production indicates that ROS production occurs upstream from caspase activation in p53-dependent apoptotic cell death induced by SPARC depletion (Supplementary Figure S3D) . p53 drives Bax upregulation to mediate apoptosis in SPARC-depleted melanoma cells To identify mediators of p53-driven ROS production and apoptosis in SPARC-depleted cells, we analyzed by real-time quantitative-polymerase chain reaction (Q-PCR) the temporal response of SPARC siRNA treatment on the expression level of several transcripts involved in p53-dependent cell-cycle arrest, apoptosis and oxidative stress regulation (Supplementary Figure S4A) . As we reported previously, genes implicated in G 2 /M cell-cycle arrest such as CDKN1A (p21 Cip1/Waf1 ) were found to be upregulated by SPARC depletion, whereas others such as CCNB1, CDC2 and CDC25C were repressed. Relevant genes also modulated by SPARC depletion included members of the Bcl-2 proapoptotic family (Bax, PUMA and Bim), the anti-apoptotic Survivin gene (BIRC5) as well as TIGAR and DRAM, two regulators of glycolysis and autophagy, respectively. In addition, SPARC depletion induced the expression of genes with antioxidant properties, such as those encoding Sestrin1, MnSOD and Foxo1. Bax, PUMA and Survivin had a similar expression pattern in both SPARC-depleted A375 and 1205Lu cells (Supplementary Figure S4B ). The expression profile that we observed in the SPARC-depleted cells is consistent with induction of p53-dependent programmed death.
At the protein level, we confirmed upregulation of Bax and decrease of Survivin upon siRNA-mediated SPARC depletion in A375, 501mel and 1205Lu cells, whereas PUMA did not change significantly (Figure 4a and Supplementary Figure S4C) . In addition, levels of Bcl-2, a critical factor for melanoma viability, were not consistently affected by siSPARC in the three melanoma lines (Supplementary Figure S4C) . Interestingly, Bax induction was preceded by progressive accumulation of p53 and induction of p21
Cip1/Waf1 in SPARC-depleted A375 cells (Figure 4a) . Notably, levels of Bax were elevated in A375 tumors after inducible knockdown of SPARC (Figure 4b ). Finally, we showed that SPARC siRNA-mediated upregulation of Bax was inhibited in A375 cells treated with siRNA to p53 and was not evidenced in p53-mutated SKmel28 cells after SPARC depletion (Figure 4c ). Figure 4d shows that increased level of Bax in response to SPARC depletion was accompanied by changes of its subcellular localization. Five days after siSPARC transfection, Bax was found to be redistributed from the cytosol fraction (F1) to the mitochondria-containing fraction (F2) concomitantly with the release of Smac/DIABLO into the cytosol.
We conducted another rescue experiment to test the contribution of Bax in apoptosis induced by SPARC depletion. We inhibited siSPARC-induced Bax expression by co-transfecting A375 and 501mel cells with an siRNA targeting Bax (Figure 4e) . In A375 cells, suppression of Bax significantly blocked SPARC siR-NA-mediated apoptosis as assessed by caspase-3 activation, PARP degradation, Annexin-V staining and ROS production (Figures 4e-g ). Significant protection against cell death was also observed with Bax siRNA in SPARC-depleted 501mel cells. Thus, Bax appears to be important for mediating the death signal induced by SPARC knockdown.
p53 is preferentially stabilized in SPARC-knockdown melanoma cells We undertook to determine how SPARC knockdown induces p53 accumulation and activation. We first examined whether SPARC deficiency upregulates p53 by a transcriptional or a posttranslational mechanism. Knockdown of SPARC in A375 cells caused a modest but non-significant increase in the levels of p53 transcripts as compared with that in control cells as determined by real-time Q-PCR (Figure 5a ), whereas in 1205Lu cells, p53 mRNA levels decreased following SPARC depletion (Supplementary Figure S4B) . However, in the presence of the translational inhibitor cycloheximide, stabilization of p53 was observed with SPARC depletion by siRNA (Figure 5b ). When control cells were treated with cycloheximide, p53 shows a halflife of about 20 min, whereas in SPARC-depleted cells, the pre-existing p53 protein was increased, with a halflife of about 60 min. These findings support the hypothesis that p53 upregulation in SPARC-depleted Figure 4 The proapoptotic BH3 family member Bax mediates apoptosis in SPARC-depleted A375 cells. (a) A375 cells were transfected with 50 nM siCTRL for 6 days, or siSPARC for various time periods. 1205Lu and 501mel cells were transfected with 50 nM siCTRL or siSPARC for 6 days. Proteins were then extracted and immunoblotting was performed using the indicated antibodies. HSP60 was used as a loading control. (b) Bax expression levels were analyzed by immunoblotting in A375 shSPARC tumor samples depleted or not for SPARC by doxycycline treatment in mice. (c) A375 cells were transfected for 6 days with control siRNA (siCTRL), p53 siRNA (sip53), SPARC siRNA (siSPARC) alone or in combination at a final concentration of 50 nM. SKmel-28 melanoma cells (TP53 mut) were transfected with 50 nM siCTRL or siSPARC for 6 days. Protein extracts from resulting cells were analyzed by immunoblotting using the indicated antibodies. (d) A375 cells were transfected with 50 nM siCTRL or siSPARC for various time periods. Translocation of Bax from cytoplasm to mitochondria was then analyzed using subcellular fractionation and immunoblotting. Cytoplasmic (F1) and mitochondrial (F2) fractions were purified as described under the Materials and methods. The release of Smac/ DIABLO from the mitochondria into the cytoplasm was shown as a control. g-Tubulin and LAMP-2 were used as purity controls for the cytoplasmic and mitochondrial fraction, respectively. (e) A375 and 501mel cells were transfected with control siRNA (siCTRL), Bax siRNA (siBax), SPARC siRNA (siSPARC) alone or in combination at a final concentration of 50 nM. The cells were harvested on day 6 after siRNA transfection. Caspase-3 activity was determined by fluorometric assay and cell proliferation by an XTT assay. The expression levels of SPARC and Bax as well as detection of cleaved PARP were analyzed by immunoblotting. (f) Quantification of apoptosis in A375 cells transfected as described above. The percentage of apoptotic cells was determined by staining the cells with Annexin-V-fluos and flow cytometry. (g) A375 cells were transfected for 6 days with siCTRL, siBax, siSPARC alone or in combination, before measurement of ROS production by flow cytometry using the redox-sensitive dye DCF-DA. ROS, reactive oxygen species; siRNA, small interfering RNA; SPARC, secreted protein acidic and rich in cysteine.
Antiapoptotic function of SPARC in melanoma cells N Fenouille et al cells is because of increased protein stability rather than a change in mRNA levels.
Posttranslational modification of p53 by phosphorylation is critical in regulating its stabilization and activation (Lavin and Gueven, 2006) . This prompted us to examine the effects of SPARC depletion on the Ser15 and Ser46 phosphorylation of p53. These sites are most commonly phosphorylated in response to DNA damage and Ser46 phosphorylation was shown to be important for p53-mediated apoptosis. A375 cells were treated with actinomycin-D as a positive control. Incubation with actinomycin-D induced the accumulation of p53 and phosphorylation at both Ser15 and Ser46 residues (Figure 5c ). By contrast, no phosphorylation was detected at any time point in cells treated with siSPARC. This suggests that SPARC knockdown causes the stabilization and activation of p53 without promoting Ser15 or Ser46 phosphorylation of p53.
SPARC regulates MDM2 and p53 through the Akt signaling pathway Another possibility that could lead to the stability of p53 would be the regulation of MDM2 by phosphorylation. Previous studies have shown that p53 can be regulated by Akt-mediated phosphorylation of MDM2 (Mayo and Donner, 2001; Zhou et al., 2001; Ogawara et al., 2002) . Phosphorylation of MDM2 promotes its localization to the nucleus, where it targets p53 for degradation and prevents p53-dependent apoptosis. As targeting SPARC expression was shown to reduce Akt activity in glioma cells (Shi et al., 2004) , we reasoned that apoptosis of SPARC-depleted melanoma cells may be caused by reduced Akt signaling. We found that transfection of A375 cells with siSPARC strongly reduced the basal activating phosphorylation of Akt on Ser473 and phosphorylation of two downstream targets glycogen synthase kinase 3b (GSK3b) and MDM2 in a time-dependent manner (Figure 6a ). Total MDM2 level also decreased in SPARC-depleted cells, which is consistent with the previous observation that phosphorylation of MDM2 by Akt leads to increased MDM2 stability (Ashcroft et al., 2002) . We confirmed these results in 1205Lu and 501mel cells that were depleted for SPARC (Figure 6a ). Of note, depletion of SPARC did not significantly affect extracellular signal-regulated kinase, p38, protein kinase C (PKC) or S6 ribosomal protein phosphorylation as well as b-catenin protein levels (Supplementary Figure S5) . We next tested whether overexpression of SPARC in melanoma cells would result in enhanced Akt signaling. We ectopically expressed an Myc-tagged SPARC construct in 501mel cells and found that overexpression of SPARC elevated phospho-Akt and phospho-MDM2 levels, indicating that SPARC promotes Akt activity in melanoma cells. Predictably, levels of p53 were lower in The expression of exogenous SPARC was confirmed using an anti-Myc tag antibody. (c) A375 cells were transfected with the indicated siRNA for 6 days. The subcellular localization of p53, MDM2 and SPARC was analyzed by subcellular fractionation and immunoblotting. Cytoplasmic (F1), mitochondrial (F2) and nuclear (F3) fractions were prepared as described under Materials and methods. g-Tubulin, LAMP-2 and histone-H1 were used as purity controls for the cytoplasmic, mitochondrial and nuclear fraction, respectively. (d) A375 cells were infected with a control empty adenovirus (AdCMV, multiplicity of infection of 2) or with adenovirus encoding the constitutively active mutant Myr-HA-Akt1 (AdAkt ca , multiplicity of infection of 2), and transfected 6 h later with 50 nM siCTRL or siSPARC for 6 days. The cells were then harvested and proteins were analyzed by immunoblotting using the indicated antibodies. (e) Quantification of apoptosis in A375 cells treated as described above. The percentage of apoptotic cells was determined by staining the cells with Annexin-V-fluos and flow cytometry. SPARC, secreted protein acidic and rich in cysteine.
SPARC-overexpressing cells compared with those in parental cells (Figure 6b ). We next asked whether SPARC knockdown alters the subcellular localization of p53 and MDM2 (Figure 6c ). Subcellular fractionation showed that, in control cells MDM2 was found in the nuclear fraction (F3). Depletion of SPARC promoted the nuclear accumulation of p53 and reduction in nuclear MDM2 levels, indicative of reduced phosphorylation and stability of MDM2. SPARC, being a secreted protein in A375 cells (Fenouille et al., 2010) , was detected predominantly associated with the microsomal fraction (F2). Taken together, these results suggest that SPARC signaling downregulates p53 levels through the Akt/MDM2 pathway.
To further probe the contribution of Akt, we analyzed whether a constitutively active form of Akt can rescue cells from apoptosis-mediated by SPARC depletion. A375 cells transfected with control or SPARC siRNAs were infected with an adenovirus control (AdCMV) or expressing Myr-Akt (AdAkt ca ). Expression of Myr-Akt induced an increase in the Ser166 phosphorylation of MDM2 concomitantly with a reduction in p53 levels, indicative of activation of Akt signaling (Figure 6d ). When constitutively active Akt was expressed together with siSPARC, no induction of p53 and Bax protein levels was observed upon SPARC knockdown. Consistently, as shown in PARP and Annexin-V assays, expression of constitutively active Akt provided protection from apoptosis induced by SPARC knockdown (Figures 6d and e) .
SPARC suppresses p53-mediated apoptosis in response to the chemotherapeutic drug actinomycin-D The RNA synthesis inhibitor actinomycin-D stimulates apoptosis mostly through activation of the p53 pathway (Choong et al., 2009) . To establish whether SPARC can modulate the p53 response, control and SPARC-overexpressing 501mel cells were treated with 1 mM actinomycin-D and cell death/survival was monitored at various time points by XTT assay (Figure 7a ). The concentration of actinomycin-D was selected after pilot experiments to determine the dose of the drug that showed survival differences between the two populations of cells. We also confirmed that at 1 mM the apoptotic effect of actinomycin-D in 501mel cells was mediated by p53 (Supplementary Figure S6) . We found that increasing SPARC expression greatly decreased the cytotoxicity of the drug, resulting in resistance to cell death compared with control cells. In accord, p53 induction in response to actinomycin-D treatment was inhibited by SPARC expression. To determine whether this phenomenon was mediated by abnormal degradation of p53, control and SPARC-overexpressing cells were treated with the proteasome inhibitor MG132, to prevent p53 degradation, in combination with actinomycin-D. MG132 pre-treatment led to better accumulation of p53 in SPARC-overexpressing cells in response to actinomycin-D and to a lesser extent also in the absence of actinomycin-D (Figure 7b) . Consistent with the stabilization result, the protective effect of SPARC on actinomycin-D-mediated apoptosis was reversed in presence of MG132 as shown by Annexin-V assays. These results support the notion that expression of SPARC promotes melanoma cell survival by increasing the proteosomal degradation of p53 under basal conditions and in response to stress.
Discussion
Unlike other solid tumors, melanomas often retain wild-type p53 protein. However, melanoma is arguably (Soengas and Lowe, 2003; Tuveson et al., 2003; Madhunapantula and Robertson, 2009) . Identification of novel pathways that alter p53 functions and counteract cell death induction is of critical importance in our current understanding of the biology of melanomas. Production of the matricellular protein SPARC is regarded as a critical event in melanoma malignancy. We recently revealed a link between SPARC and p53, and proposed that some pro-tumorigenic functions of SPARC may be because of relaxation of a p53-dependent G 2 /M checkpoint (Fenouille et al., 2011) . The signaling pathways whereby SPARC controls p53, however, remain to be identified. In this study, we show that SPARC produced autonomously by melanoma cells activates the antiapoptotic Akt signaling pathway to limit p53 levels through phosphorylation of MDM2. This process protects cells that retained wild-type p53 from apoptosis induced by treatment with the anticancer drug actinomycin-D.
Our data showed that wild-type, p53-expressing melanoma cells are sensitive to SPARC depletion as compared with melanoma cells that harbor mutant copies of p53. Knockdown of SPARC resulted in mitochondrial apoptotic death associated with p53 protein stabilization, Bax transcriptional induction and its translocation to mitochondria, followed by ROS generation and activation of caspase-9 and caspase-3. We also provided evidence that induction of apoptosis in SPARC-depleted cells is p53-dependent and that one of the main downstream mediators of p53 in this death process is Bax. However, despite the evidence presented for the role of Bax in apoptosis, we cannot completely exclude the possibility that other p53 targets such as Survivin that were found to be regulated by SPARC knockdown contribute to this process.
The generation of ROS in SPARC-depleted melanoma cells is consistent with a recent study showing that SPARC-null epithelial cells have constitutive increased basal levels of ROS compared with wild-type cells (Weaver et al., 2008) . ROS are important downstream mediators of apoptosis triggered by p53 (Johnson et al., 1996) . The requirement of Bax to ROS increase that we observed is consistent with the notion of a mitochondrial role in ROS production after upregulation of p53. Finally, our observations that melanoma cells overexpressing SPARC are more resistant to p53-mediated apoptosis induced by actinomycin-D provide proof-ofconcept evidence that the pathological elevations of SPARC frequently observed in melanomas might be important for maintaining cell survival through inactivation of p53 functions.
We confirmed our previous findings that p53 is activated following SPARC depletion in cells and xenograft tumors (Fenouille et al., 2011) . Activation of p53 in SPARC-depleted cells promoted an early induction of p21 Cip1/Waf1 and G 2 /M cell-cycle arrest that is followed by Bax induction and apoptosis. It is not fully understood how melanoma cells undergo apoptosis at the G 2 /M checkpoint. However, our present data show that the duration of p53 accumulation following SPARC deficiency then resulted in the upregulation of Bax, whereas p21
Cip1/Waf1 levels remained constant. Such sequential kinetics of p21
Cip1/Waf1 and Bax expression might explain the cell fate decision in SPARC-knockdown cells.
We went further to address how SPARC modulates p53 and observed that SPARC knockdown mediates p53 activation in the absence of markers of DNA damage (that is, Ser15 or Ser46 phosphorylation of p53). Instead, we found that SPARC activates Akt and phosphorylation of MDM2 at Ser166, which was identified as a site of activating phosphorylation by Akt (Zhou et al., 2001; Ogawara et al., 2002) . Conversely, SPARC depletion lowered the amount of Akt and MDM2 phosphorylation, and reduced the levels of nuclear MDM2, which is in agreement with the notion that Akt-mediated MDM2 phosphorylation increases its stability (Ashcroft et al., 2002) . These observations combined with our data obtained using MG132 make it very likely that SPARC signaling through Akt downregulates p53 by activation of MDM2-mediated ubiquitination and degradation of p53. Importantly, we showed that activated Akt prevents the apoptosis hallmarks of SPARC-depleted cells. It is thus likely that SPARC knockdown-induced inhibition of Akt signaling is responsible for the p53-mediated apoptosis reported here. Although a previous work showed that SPARC activates Akt to mediate its antiapoptotic function in glioma cells (Shi et al., 2004) , the observation that SPARC downregulates p53 through Akt-mediated activating phosphorylation of MDM2 is a novel and unprecedented finding.
Integrins have emerged as potential cellular receptors for SPARC. SPARC was shown to interact with integrin-b1 (Nie et al., 2008; Weaver et al., 2008) , and reports suggested that integrins avb3 and avb5 can mediate some effects of SPARC (De et al., 2003; Sangaletti et al., 2008) . Integrin-avb3 has been linked to melanoma progression and SPARC expression (Sturm et al., 2002) , and is required for melanoma cell survival (Montgomery et al., 1994) . Interestingly, integrin-avb3 ligation can counteract p53 activation in vascular endothelial cells (Stromblad et al., 1996) . Further research is thus required to determine whether SPARC inactivates p53 through binding to melanoma integrin-avb3.
The role of SPARC in cell survival and death is complex. SPARC was originally identified as a stress response gene (Sage et al., 1986) , and subsequently described as a c-Jun-responsive target gene that can be repressed or induced depending on cell type (Mettouchi et al., 1994; Briggs et al., 2002) . Consistent with a role of SPARC in cellular stress, recent studies showed that SPARC protects lens epithelial cells from stress-induced apoptosis and suppresses apoptosis in pulmonary fibroblasts (Weaver et al., 2008; Chang et al., 2010) .
In addition, a pro-survival activity for SPARC in gliomas was documented (Shi et al., 2004) . Our findings agree with these observations and indicate that SPARC functions to prevent stress-induced apoptosis in melanoma cells. Interestingly, the Drosophila homolog of SPARC was recently shown to mediate a self-protective signal during the cell competition process (Portela et al., 2010) . Thus, the stress protection function of SPARC appears to be evolutionarily conserved between flies and humans. On the other hand, there is evidence in some contexts that SPARC induces apoptosis in ovarian cancer cells (Yiu et al., 2001) and modulates sensitivity to chemotherapy in colon cancer cells by enhancing apoptosis (Tang and Tai, 2007) .
SPARC may exert its pro-or anti-tumorigenic effects through multiple mechanisms, but our study shows that the antiapoptotic function of SPARC is mediated through p53. Hence, some features of SPARC on tumor biology might be related to the p53 status of cancer cells. It is therefore possible that its paradoxical role in tumorigenesis is a result of SPARC's inhibitory effect toward p53. Interestingly, it has been shown that p53 activation leads to the inhibition of SPARC secretion in human glioma cells (Khwaja et al., 2006) . This, combined with our observation that SPARC negatively regulates p53 function, argues in favor of a regulatory feedback loop between SPARC and p53. It is tempting to speculate that in melanomas, this loop would result in increased SPARC secretion in the tumor microenvironment and, in turn, further inhibition of the p53 pathway.
In conclusion, we propose that SPARC can promote melanoma survival through tumor cell-autonomous signaling that involves Akt/MDM2-mediated p53 degradation. Importantly, the sensitivity of wild-type p53-carrying melanoma cells to SPARC removal indicates that their survival is reliant on SPARC levels. Reactivation of p53-dependent cell death programs has been proposed previously for therapeutic intervention for melanomas with a wild-type p53 status (Soengas et al., 2001; Smalley et al., 2007) . Our study shows the efficacy of SPARC RNA interference to activate a p53 response leading to apoptosis. In melanoma cases that retain intact p53, targeting SPARC may thus be a promising strategy to impede the progression of this lethal form of skin cancer.
Materials and methods
Cell lines, siRNA, antibodies and reagents Human melanoma cell lines with known p53 status were maintained as described by Fenouille et al. (2011) . A375 cells stably expressing doxycycline-inducible SPARC shRNA and 501mel cells expressing an Myc-tagged human SPARC (501mel SPARC) were described previously by Fenouille et al. (2011) . The list of antibodies used and details of siRNA are included in the Supplementary information. Adenoviruses carrying an empty expression cassette of pcDNA3 vector, used as control or expressing the constitutively active mutant of Akt1, Myr-HA-Akt1, were purchased from Vector Biolabs (Philadelphia, PA, USA). Adenoviruses were amplified as described earlier by Gaggioli et al. (2005) . Chemicals were obtained from Sigma-Aldrich (St Louis, MO, USA).
